{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:07:51Z","timestamp":1746331671397,"version":"3.40.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Regional Science Fund Project","award":["8216010104"],"award-info":[{"award-number":["8216010104"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Primary plasma cell leukemia is a rare and highly aggressive malignancy of the blood system, with rapid disease progression and a high early mortality rate. Currently, there is no recognized therapeutic regimen, leading to the adoption of strategies typically utilized for multiple myeloma, which, however, exhibit limited efficacy. Selinexor is considered effective in treating relapsed\/refractory multiple myeloma, but there are currently no reports on its application in primary plasma cell leukemia. Here, we reported a case of primary plasma cell leukemia with multiple high-risk genetic factors (including 1q21+, 17p\u2010, and 13q\u2010) who received a chemotherapy regimen including selinexor, pomalidomide, and dexamethasone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>This case was a 58-year-old male presenting with lower back pain, abdominal pain, and various systemic symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The initial diagnosis of intestinal obstruction at a local hospital was followed by a referral to our emergency department due to abnormal blood test results indicative of a hematologic disorder. Further investigations confirmed a rare diagnosis of primary plasma cell leukemia of the IgA-k light chain subtype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was promptly treated with a chemotherapy regimen comprising selinexor, pomalidomide, and dexamethasone in addition to supportive care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Subsequent assessments showed a significant response to treatment, with improvement in symptoms, normalization of blood parameters, and achievement of very good partial response. However, due to financial constraints, the patient declined hematopoietic stem cell transplantation and eventually opted to discontinue treatment, leading to disease progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The combination of selinexor with pomalidomide and dexamethasone has shown good efficacy in primary plasma cell leukemia with high-risk genetic abnormalities. Our case may provide evidence for developing an effective selinexor-based regimen for treating primary plasma cell leukemia with high-risk genetic abnormalities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040447","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:03:05Z","timestamp":1732032185000},"page":"e40447","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0864-3696","authenticated-orcid":false,"given":"Wenxia","family":"Fan","sequence":"first","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyou","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingling","family":"Sun","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Abduklimu","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-9541","authenticated-orcid":false,"given":"Xinhong","family":"Guo","sequence":"additional","affiliation":[{"name":"Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy.","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma.","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","article-title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.","volume":"14","author":"Neupane","year":"2024","journal-title":"Blood Cancer J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jha2.122","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"2","author":"Gasparetto","year":"2021","journal-title":"EJHaem"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139858","article-title":"Selinexor in combination with pomalidomide and dexamethasone (SPd) for treatment of patients with relapsed refractory multiple myeloma (RRMM).","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.","volume":"27","author":"Fernandez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2022.2022033","article-title":"Update on primary plasma cell leukemia.","volume":"57","author":"Jung","year":"2022","journal-title":"Blood Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-020-0307-4","article-title":"Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.","volume":"10","author":"Mina","year":"2020","journal-title":"Blood Cancer J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma\u2014a meta-analysis of 2,596 trial patients.","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-139340","article-title":"The genomic and transcriptomic landscape of plasma cell leukemia.","volume":"136","author":"Cazaubiel","year":"2020","journal-title":"Blood"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1002\/ajh.25676","article-title":"The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis.","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-021-01071-9","article-title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.","volume":"14","author":"Mateos","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-137060","article-title":"Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial.","volume":"136","author":"D\u2019Agostino","year":"2020","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:02:54Z","timestamp":1746320574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":17,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040447","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}